Completed PHASE4 INTERVENTIONAL 2-arm NCT02230371

Study on the Effect of Granisetron on Myofascial Pain in the Orofacial Muscles

The Serotonin Receptor Type 3 Antagonist Granisetron as a New Treatment Approach for Patients With Chronic Myofascial Pain in the Orofacial Muscles

Sponsor: Folktandvården Stockholms län AB

Conditions Myofascial Pain Temporomandibular Disorders

Interventions Control (placebo) Granisetron

Updated 6 times since 2017 Last updated: Mar 23, 2021 Started: Mar 31, 2007 Primary completion: Oct 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Myofascial Pain and Temporomandibular Disorders and is currently completed. Folktandvården Stockholms län AB leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Apr 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Apr 2021 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Mar 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Folktandvården Stockholms län AB
Karolinska Institutet

Data source: Karolinska Institutet

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Huddinge, Sweden